Eliglustat and Abiraterone: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Eliglustat
Abiraterone
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased eliglustat exposure and an increased risk of cardiac arrhythmias from prolongation of the PR, QTc and/or QRS cardiac intervals
Interaction Deep Dive
Coadministration with CYP2D6 inhibitors is predicted to increase eliglustat AUC 4.5-fold to 8.4-fold in extensive metabolizers, and 1.6-fold to 2.3-fold in intermediate metabolizers. In patients with Gaucher disease type 1 (GD1) who are extensive and intermediate CYP2D6 metabolizers, reduce the eliglustat dose to 84 mg once daily when used concomitantly with a strong or moderate CYP2D6 inhibitor. And, in patients who are CYP2D6 poor metabolizers continue eliglustat 84 mg to once daily1.
Why it happens (mechanism)
Inhibition of CYP2D6-mediated metabolism of eliglustat
Literature reports
2 reports — tap to read
a) Coadministration of eliglustat 84 mg twice daily with the strong CYP2D6 inhibitor PARoxetine (30 mg/day) led to 7-fold and 8.4-fold increases in eliglustat Cmax and AUC, respectively, in extensive CYP2D6 metabolizers with Gaucher disease type 1 (N=30). Intermediate CYP2D6 metabolizers were predicted to experience 2.1- and 2.3-fold increases in eliglustat Cmax and AUC, respectively. Among extensive CYP2D6 metabolizers treated with eliglustat and terbinafine, simulations suggested that coadministration would cause eliglustat Cmax and AUC to rise 3.8-fold and 4.5-fold, respectively, and to increase 1.6-fold in intermediate CYP2D6 metabolizers 1.
b) Among extensive CYP2D6 metabolizers with Gaucher disease type 1, simulations suggested that eliglustat Cmax would increase 16.7-fold and AUC would increase 24.2-fold with concomitant use of ketoconazole (a strong CYP3A inhibitor) plus PARoxetine (a strong CYP2D6 inhibitor). Among intermediate metabolizers, the predicted eliglustat Cmax would increase 7.5-fold and AUC would increase 9.8-fold with concurrent use of ketoconazole plus PARoxetine. Among extensive CYP2D6 metabolizers with Gaucher disease type 1, simulations suggested that eliglustat Cmax would increase 10.2-fold and AUC would increase 13.6-fold with concomitant use of fluconazole (a moderate CYP3A inhibitor) plus terbinafine (a strong CYP2D6 inhibitor). Among intermediate CYP2D6 metabolizers, the predicted eliglustat Cmax and AUC was 4.2- and 5-fold higher, respectively, with concurrent use of fluconazole plus terbinafine 1.
Common questions
Can I take Eliglustat and Abiraterone together?
Increased eliglustat exposure and an increased risk of cardiac arrhythmias from prolongation of the PR, QTc and/or QRS cardiac intervals Always confirm with your pharmacist or prescriber before making any change.
How serious is the Eliglustat and Abiraterone interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Eliglustat or Abiraterone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CERDELGA(R) oral capsules, eliglustat oral capsules. Genzyme Corporation (per FDA, Cambridge, MA, 2018. DailyMed
Keep reading about Eliglustat
Keep reading about Abiraterone
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist